Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Child Neurol ; 33(13): 832-836, 2018 11.
Artigo em Inglês | MEDLINE | ID: mdl-30182801

RESUMO

Three children with drug-refractory epilepsy, normal magnetic resonance image (MRI), and a heterozygous SCN1A variant underwent 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography (FDG-PET) scanning between age 6 months and 1 year and then at age 3 years 6 months to 5 years 5 months. Regional FDG uptake values were compared to those measured in age- and gender-matched pseudo-controls. At baseline, the brain glucose metabolic pattern in the SCN1A group was similar to that of the pseudo-controls. At follow-up, robust decreases of normalized FDG uptake was found in bilateral frontal, parietal and temporal cortex, with milder decreases in occipital cortex. Children with epilepsy and an SCN1A variant have a normal pattern of cerebral glucose metabolism at around 1 year of age but develop bilateral cortical glucose hypometabolism by age 4 years, with maximal decreases in frontal, parietal, and temporal cortex. This metabolic pattern may be characteristic of epilepsy associated with SCN1A variants and may serve as a biomarker to monitor disease progression and response to treatments.


Assuntos
Encéfalo/metabolismo , Epilepsia/genética , Transtornos do Metabolismo de Glucose/genética , Mutação/genética , Canal de Sódio Disparado por Voltagem NAV1.1/genética , Encéfalo/diagnóstico por imagem , Criança , Pré-Escolar , Epilepsia/complicações , Epilepsia/diagnóstico por imagem , Feminino , Fluordesoxiglucose F18/farmacocinética , Transtornos do Metabolismo de Glucose/complicações , Transtornos do Metabolismo de Glucose/diagnóstico por imagem , Humanos , Estudos Longitudinais , Masculino , Tomografia por Emissão de Pósitrons , Estudos Retrospectivos
2.
J Alzheimers Dis ; 60(1): 225-233, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28826182

RESUMO

BACKGROUND: Weight loss is frequently observed in patients with Alzheimer's disease (AD); however, the underlying mechanisms are not well understood. OBJECTS: To clarify the associations between nutritional status and AD-related brain changes using Pittsburgh Compound-B (PiB)-PET, fluorodeoxyglucose (FDG)-PET, and structural MRI. METHODS: The subjects were 34 amyloid-ß (Aß)-positive individuals with mild cognitive impairment or early AD (prodromal/early AD), and 55 Aß-negative cognitively normal (CN) subjects who attended the Multimodal Neuroimaging for AD Diagnosis (MULNIAD) study. Nutritional status of the subjects was assessed by body mass index and waist to height ratio (waist circumference/height). The associations between nutritional status and brain changes were examined by multiple regression analysis using statistical parametric mapping. RESULTS: In the prodromal/early AD group, nutritional status was significantly positively correlated with regional cerebral glucose metabolism (rCGM) in the medial prefrontal cortices, while different topographical associations were seen in the CN group, suggesting these changes were AD-specific. Aß deposition and gray matter volume were not significantly associated with nutritional status. Sub-analysis in the prodromal/early AD group demonstrated that fat mass index, but not fat-free mass index, was positively correlated with rCGM in the medial prefrontal areas. CONCLUSION: This present study provides preliminary results suggesting that hypometabolism in the medial prefrontal areas is specifically associated with AD-related weight loss, and decrease in fat mass may have a key role.


Assuntos
Doença de Alzheimer/patologia , Doença de Alzheimer/fisiopatologia , Transtornos do Metabolismo de Glucose/etiologia , Estado Nutricional/fisiologia , Córtex Pré-Frontal/metabolismo , Sintomas Prodrômicos , Idoso , Doença de Alzheimer/diagnóstico por imagem , Compostos de Anilina/metabolismo , Transtornos Cognitivos/etiologia , Feminino , Transtornos do Metabolismo de Glucose/diagnóstico por imagem , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Tomografia por Emissão de Pósitrons , Córtex Pré-Frontal/diagnóstico por imagem , Escalas de Graduação Psiquiátrica , Tiazóis/metabolismo
3.
Int J Mol Sci ; 17(10)2016 Oct 18.
Artigo em Inglês | MEDLINE | ID: mdl-27763550

RESUMO

Alzheimer's disease (AD) is a leading cause of dementia worldwide, associated with cognitive deficits and brain glucose metabolic alteration. However, the associations of glucose metabolic changes with cognitive dysfunction are less detailed. Here, we examined the brains of APP/presenilin 1 (PS1) transgenic (Tg) mice aged 2, 3.5, 5 and 8 months using 18F-labed fluorodeoxyglucose (18F-FDG) microPET to assess age- and brain region-specific changes of glucose metabolism. FDG uptake was calculated as a relative standardized uptake value (SUVr). Morris water maze (MWM) was used to evaluate learning and memory dysfunction. We showed a glucose utilization increase in multiple brain regions of Tg mice at 2 and 3.5 months but not at 5 and 8 months. Comparisons of SUVrs within brains showed higher glucose utilization than controls in the entorhinal cortex, hippocampus, and frontal cortex of Tg mice at 2 and 3.5 months but in the thalamus and striatum at 3.5, 5 and 8 months. By comparing SUVrs in the entorhinal cortex and hippocampus, Tg mice were distinguished from controls at 2 and 3.5 months. In MWM, Tg mice aged 2 months shared a similar performance to the controls (prodromal-AD). By contrast, Tg mice failed training tests at 3.5 months but failed all MWM tests at 5 and 8 months, suggestive of partial or complete cognitive deficits (symptomatic-AD). Correlation analyses showed that hippocampal SUVrs were significantly correlated with MWM parameters in the symptomatic-AD stage. These data suggest that glucose metabolic disorder occurs before onset of AD signs in APP/PS1 mice with the entorhinal cortex and hippocampus affected first, and that regional FDG uptake increase can be an early biomarker for AD. Furthermore, hippocampal FDG uptake is a possible indicator for progression of Alzheimer's cognition after cognitive decline, at least in animals.


Assuntos
Doença de Alzheimer/diagnóstico por imagem , Precursor de Proteína beta-Amiloide/genética , Encéfalo/diagnóstico por imagem , Transtornos do Metabolismo de Glucose/diagnóstico por imagem , Presenilina-1/genética , Envelhecimento , Doença de Alzheimer/genética , Doença de Alzheimer/metabolismo , Doença de Alzheimer/patologia , Animais , Encéfalo/metabolismo , Encéfalo/patologia , Cognição , Modelos Animais de Doenças , Feminino , Fluordesoxiglucose F18/análise , Glucose/análise , Glucose/metabolismo , Transtornos do Metabolismo de Glucose/genética , Transtornos do Metabolismo de Glucose/metabolismo , Transtornos do Metabolismo de Glucose/patologia , Hipocampo/diagnóstico por imagem , Hipocampo/metabolismo , Hipocampo/patologia , Humanos , Aprendizagem em Labirinto , Transtornos da Memória/diagnóstico por imagem , Transtornos da Memória/genética , Transtornos da Memória/metabolismo , Transtornos da Memória/patologia , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Mutação , Tomografia por Emissão de Pósitrons
4.
BMC Psychiatry ; 15: 157, 2015 Jul 11.
Artigo em Inglês | MEDLINE | ID: mdl-26163145

RESUMO

BACKGROUND: With aging of society the absolute number and the proportion of patients with cognitive deficits increase. Multiple disorders and diseases can foster cognitive impairment, e.g., Alzheimer's disease (AD), depressive disorder, or polypharmacy. CASE PRESENTATION: A 74 year old man presented to the Old Age Psychiatry Service with cognitive deficits while being treated for recurrent depressive episodes and essential tremor with Venlafaxine, Lithium, and Primidone. Neuropsychological testing revealed a medio-temporal pattern of deficits with pronounced impairment of episodic memory, particularly delayed recall. Likewise, cognitive flexibility, semantic fluency, and attention were impaired. Positron emission tomography (PET) with fluorodeoxyglucose was performed and revealed a pattern of glucose utilization deficit resembling AD. On cessation of treatment with Lithium and Primidone, cognitive performance improved, particularly episodic memory performance and cognitive flexibility. Likewise, glucose metabolism normalized. Despite normalization of both, clinical symptoms and glucose utilization, the patient remained worried about possible underlying Alzheimer's disease pathology. To rule this out, an amyloid-PET was performed. No cortical amyloid was observed. CONCLUSION: Pharmacological treatment of older subjects may mimic glucose metabolism and clinical symptoms of Alzheimer's disease. In the present case both, imaging and clinical findings, reversed to normal on change of treatment. Amyloid PET is a helpful tool to additionally rule out underlying Alzheimer's disease in situations of clinical doubt even if clinical or other imaging findings are suggestive of Alzheimer's disease.


Assuntos
Antidepressivos/efeitos adversos , Transtornos Cognitivos/induzido quimicamente , Transtorno Depressivo Maior/tratamento farmacológico , Transtornos do Metabolismo de Glucose/induzido quimicamente , Transtornos da Memória/induzido quimicamente , Idoso , Doença de Alzheimer/diagnóstico por imagem , Anticonvulsivantes/efeitos adversos , Atenção/efeitos dos fármacos , Transtornos Cognitivos/diagnóstico por imagem , Transtorno Depressivo Maior/diagnóstico por imagem , Diagnóstico Diferencial , Quimioterapia Combinada , Tremor Essencial/tratamento farmacológico , Fluordesoxiglucose F18 , Transtornos do Metabolismo de Glucose/diagnóstico por imagem , Humanos , Compostos de Lítio/efeitos adversos , Masculino , Transtornos da Memória/diagnóstico por imagem , Memória Episódica , Rememoração Mental/efeitos dos fármacos , Testes Neuropsicológicos , Tomografia por Emissão de Pósitrons/métodos , Primidona/efeitos adversos , Compostos Radiofarmacêuticos , Recidiva , Cloridrato de Venlafaxina/efeitos adversos
5.
Clin Exp Ophthalmol ; 43(8): 711-9, 2015 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25904022

RESUMO

BACKGROUND: It has recently become clear that glaucoma is not only an ocular disease, but involves central visual pathways as well. The purpose of this study was to examine functional and structural alterations in the brains of glaucoma patients. DESIGN: Case-control study in a hospital. PARTICIPANTS: A total of 32 glaucoma patients and 19 healthy controls. METHODS: All participants underwent positron emission tomography with (18)F-fluorodeoxyglucose, diffusion-tensor magnetic resonance imaging, and the 30-2 program of the Humphrey Visual Field Analyzer. MAIN OUTCOME MEASURES: Fractional anisotropy values of the optic radiation were compared between the two groups by defining regions of interests. Cerebral glucose metabolism was compared using statistical parametric mapping software. The correlation coefficients were calculated between the average of the total deviation of hemivisual fields of both eyes, fractional anisotropy values of the contralateral optic radiation and glucose metabolism in the contralateral striate cortex. RESULTS: Fractional anisotropy values in the bilateral optic radiations were significantly lower in patients with glaucoma. A significant glucose hypometabolism in the bilateral striate cortex was also observed in the glaucoma group. Regression analyses for glaucoma patients demonstrated that the average of the total deviation of hemivisual fields significantly correlated with both fractional anisotropy value of the contralateral optic radiation and glucose metabolism in the contralateral striate cortex. Moreover, there were significant correlations between fractional anisotropy values of the optic radiation and ipsilateral striatal glucose metabolism. CONCLUSION: We observed structural alterations in the bilateral optic radiations and glucose hypometabolism in the bilateral striate cortex of glaucoma patients.


Assuntos
Glaucoma/metabolismo , Transtornos do Metabolismo de Glucose/metabolismo , Doenças do Nervo Óptico/metabolismo , Transtornos da Visão/metabolismo , Córtex Visual/metabolismo , Campos Visuais , Adulto , Idoso , Idoso de 80 Anos ou mais , Anisotropia , Glicemia/metabolismo , Estudos de Casos e Controles , Imagem de Difusão por Ressonância Magnética , Feminino , Fluordesoxiglucose F18/administração & dosagem , Glaucoma/diagnóstico por imagem , Transtornos do Metabolismo de Glucose/diagnóstico por imagem , Humanos , Masculino , Pessoa de Meia-Idade , Doenças do Nervo Óptico/diagnóstico por imagem , Tomografia por Emissão de Pósitrons , Estudos Prospectivos , Transtornos da Visão/diagnóstico por imagem , Córtex Visual/diagnóstico por imagem , Testes de Campo Visual
6.
J Alzheimers Dis ; 25(3): 517-23, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21471644

RESUMO

Intracerebroventricular injection of streptozotocin (icv-STZ) in rodents induces cellular and behavioral features mimicking Alzheimer's disease (AD). However, the effect of icv-STZ in terms of regional cerebral glucose metabolism has not yet been examined in vivo. Given that regionally specific hypometabolism of glucose is a consistent neuroimaging marker in early AD, we monitored 18F-deoxyglucose uptake using a high-resolution micro-PET after icv-STZ in non-human primates. Two cynomolgus monkeys (Macaca fascicularis) received STZ (2 mg/kg), and another two were given normal saline as controls, at the cerebellomedullary cistern (CM) three times (day 1, 7, and 14). FDG-PET, as well as MRI for structural evaluation, was performed immediately before, six weeks after, and 12 weeks after the first icv injection. In the STZ group, FDG uptake decreased significantly in comparison to the pre-injection baseline, at the precuneus, the posterior cingulate, and medial temporal cortices. Increase in sulcal markings suggesting brain atrophy was observed by MRI at six weeks post-injection. The structural changes normalized at 12 weeks, but the reduced FDG uptake persisted at the same loci. The cortical distribution of glucose hypometabolism was similar to that at early stages of AD patients. The findings demonstrate that the effect of icv-STZ is regionally specific, lending further support for the method as a model of AD pathogenesis.


Assuntos
Doença de Alzheimer/complicações , Encéfalo/patologia , Transtornos do Metabolismo de Glucose/etiologia , Transtornos do Metabolismo de Glucose/patologia , Estreptozocina/toxicidade , Doença de Alzheimer/induzido quimicamente , Animais , Encéfalo/diagnóstico por imagem , Encéfalo/efeitos dos fármacos , Mapeamento Encefálico , Modelos Animais de Doenças , Fluordesoxiglucose F18 , Transtornos do Metabolismo de Glucose/diagnóstico por imagem , Injeções Intraventriculares , Macaca fascicularis , Imageamento por Ressonância Magnética , Tomografia por Emissão de Pósitrons/métodos , Fatores de Tempo
7.
Neurobiol Aging ; 29(5): 676-92, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-17222480

RESUMO

OBJECTIVE: This longitudinal study used FDG-PET imaging to predict and monitor cognitive decline from normal aging. METHODS: Seventy-seven 50-80-year-old normal (NL) elderly received longitudinal clinical examinations over 6-14 years (561 person-years, mean per person 7.2 years). All subjects had a baseline FDG-PET scan and 55 subjects received follow-up PET exams. Glucose metabolic rates (MRglc) in the hippocampus and cortical regions were examined as predictors and correlates of clinical decline. RESULTS: Eleven NL subjects developed dementia, including six with Alzheimer's disease (AD), and 19 declined to mild cognitive impairment (MCI), on average 8 years after the baseline exam. The baseline hippocampal MRglc predicted decline from NL to AD (81% accuracy), including two post-mortem confirmed cases, from NL to other dementias (77% accuracy), and from NL to MCI (71% accuracy). Greater rates of hippocampal and cortical MRglc reductions were found in the declining as compared to the non-declining NL. CONCLUSIONS: Hippocampal MRglc reductions using FDG-PET during normal aging predict cognitive decline years in advance of the clinical diagnosis. Future studies are needed to increase preclinical specificity in differentiating dementing disorders.


Assuntos
Envelhecimento/metabolismo , Transtornos Cognitivos/metabolismo , Demência/diagnóstico por imagem , Fluordesoxiglucose F18/farmacocinética , Transtornos do Metabolismo de Glucose/metabolismo , Glucose/metabolismo , Hipocampo/metabolismo , Idoso , Idoso de 80 Anos ou mais , Transtornos Cognitivos/complicações , Transtornos Cognitivos/diagnóstico por imagem , Demência/metabolismo , Feminino , Transtornos do Metabolismo de Glucose/complicações , Transtornos do Metabolismo de Glucose/diagnóstico por imagem , Hipocampo/diagnóstico por imagem , Humanos , Masculino , Pessoa de Meia-Idade , Cintilografia , Compostos Radiofarmacêuticos/farmacocinética , Estatística como Assunto
9.
Ann Nucl Med ; 19(3): 231-4, 2005 May.
Artigo em Inglês | MEDLINE | ID: mdl-15981677

RESUMO

A 65-year-old male with an old cerebral contusion in the frontal lobes had suffered from status complex partial seizures. Ictal positron emission tomography with an F-18 fluorodeoxyglucose ([18F]FDG-PET) scan revealed hypermetabolism in the frontal, temporal and parietal lobes and the contralateral cerebellar hemisphere. The patient underwent a next-day PET scan with the 15O-labeled gas inhalation technique, which showed mild hyperperfusion and oxygen hypermetabolism in these areas. An interictal [18F]FDG-PET scan 17 days after the initial epilepsy demonstrated glucose hypometabolism of the frontal, temporal and parietal lobes and the contralateral cerebellar hemisphere. Increased glucose metabolism on the interictal PET scan and decreased glucose metabolism on an interictal PET scan in the epileptogenic supratentorial zones and the contralateral cerebellar hemisphere are interesting observations for understanding the pathophysiology in long-standing partial seizures.


Assuntos
Cerebelo/diagnóstico por imagem , Córtex Cerebral/diagnóstico por imagem , Epilepsia/diagnóstico por imagem , Fluordesoxiglucose F18 , Transtornos do Metabolismo de Glucose/diagnóstico por imagem , Idoso , Lesões Encefálicas/complicações , Cerebelo/metabolismo , Córtex Cerebral/metabolismo , Epilepsia/etiologia , Epilepsia/metabolismo , Fluordesoxiglucose F18/farmacocinética , Glucose/metabolismo , Transtornos do Metabolismo de Glucose/etiologia , Transtornos do Metabolismo de Glucose/metabolismo , Humanos , Masculino , Tomografia por Emissão de Pósitrons/métodos , Compostos Radiofarmacêuticos/farmacocinética
10.
J Neurol Sci ; 215(1-2): 71-4, 2003 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-14568131

RESUMO

OBJECTIVE: To investigate the cerebral glucose metabolism of subjects who had a Clinical Dementia Rating (CDR) of 0.5, we studied 40 subjects whose CDR was 0.5 and 40 age-matched healthy subjects. METHODS: Cerebral glucose image of each subject was obtained by [18F]-2-fluoro-deoxy-D-glucose (FDG) positron emission tomography (PET). The anatomically standardized images were produced with NEUROSTAT. Then, the two groups were compared with the Statistical Parametric Mappings (SPM) 99. RESULTS: A comparison with the SPM 99 revealed that relative cerebral glucose metabolism was lower in the posterior cingulate gyri and parietal lobules in the CDR 0.5 group than in the healthy subjects group. CONCLUSION: These findings are very similar to those in patients with probable Alzheimer's disease (AD) and suggest that the majority of subjects with CDR 0.5 are suffering from very mild AD or at least a prodromal state of AD.


Assuntos
Demência/diagnóstico por imagem , Demência/psicologia , Transtornos do Metabolismo de Glucose/diagnóstico por imagem , Transtornos do Metabolismo de Glucose/psicologia , Escalas de Graduação Psiquiátrica , Idoso , Demência/metabolismo , Feminino , Transtornos do Metabolismo de Glucose/metabolismo , Humanos , Masculino , Pessoa de Meia-Idade , Escalas de Graduação Psiquiátrica/estatística & dados numéricos , Tomografia Computadorizada de Emissão/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...